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Abstract
Background:  Traumatic injuries occurring in agricultural settings are often associated with
infections caused by unusual organisms. Such agents may be difficult to isolate, identify, and treat
effectively.
Case report: A 4-year-old boy developed an extensive infection of his knee and distal femur
following a barnyard pitchfork injury. Ultimately the primary infecting agent was determined to be
Myceliophthora thermophila, a thermophilic melanized hyphomycete, rarely associated with human
infection, found in animal excreta. Because of resistance to standard antifungal agents including
amphotericin B and caspofungin, therapy was instituted with a prolonged course of terbinafine and
voriconazole. Voriconazole blood levels demonstrated that the patient required a drug dosage
(13.4 mg/kg) several fold greater than that recommended for adults in order to attain therapeutic
blood levels.
Conclusion:  Unusual pathogens should be sought following traumatic farm injuries.
Pharmacokinetic studies may be of critical importance when utilizing antifungal therapy with agents
for which little information exists regarding drug metabolism in children.
Myceliophthora thermophila is a thermophilic phaeoid
mould found in pasture soil, wood chips, straw, mouldy
hay, compost piles and other environmental settings
where heat is generated. It is also found in the excreta and
rumen of cattle and is a pathogen of cultivated mush-
rooms [1]. A rare cause of invasive human infections, it
can be difficult to isolate and identify in clinical speci-
mens. We recently cared for a 4-1/2 year old boy who
developed osteomyelitis of the distal femur caused by
direct inoculation of Myceliophthora thermophila via a
pitchfork injury to his knee. The patient demonstrated
severe destructive osseous and cartilaginous infection,
with slow clinical improvement, requiring the prolonged
use of multiple antifungal agents. Due to the limited
number of agents to which this organism was susceptible,
voriconazole therapy was instituted despite limited phar-
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macokinetic data in children. Prolonged therapy with ter-
binafine, a drug generally employed for superficial
saprophytic infections of skin and nails also was utilized.
This case demonstrates the difficulties that can be encoun-
tered in identifying and treating this unusual but aggres-
sive fungal organism.
Case report
A 4-1/2 year old boy presented with a swollen right knee
after being impaled in that area by a pitchfork. The pitch-
fork was observed to be contaminated with cow manure
and hay. The knee was washed with soap and water. The
following morning the knee was swollen and the boy was
treated with orally administered antibiotics.
The mobility of the knee progressively decreased, and four
days later the child was admitted to the hospital. Bacterial
cultures of joint fluid yielded Bacillus and Enterococcus
species. After a brief course of intravenous antibiotic ther-
apy, the boy was discharged to continue orally adminis-
tered antibiotics. At home, he developed increasing knee
pain with inability to walk. A magnetic resonance image
(MRI) obtained at transfer to our institution was consist-
ent with infection involving the synovium, the medial
femoral condyle and adjacent articular cartilage. Intrave-
nous antibacterial therapy was instituted with vancomy-
cin, piperacillin-tazobactam and amikacin.
Twenty seven days after the initial pitchfork injury, the
patient was returned to the operating room because of
persistent leg and knee swelling as well as increasing ele-
vation of inflammatory markers with an ESR of >100 and
a CRP of 6.5. An MRI revealed apparent osteomyelitis of
the medial femoral condyle. New bone cultures were
obtained which grew what was initially identified as a der-
matophyte. Orally administered terbinafine, 125 mg (6.7
mg/kg) daily, was initiated, and the patient began to
improve clinically. His CRP declined to a nadir of 1.8 with
absence of fever and better movement of his leg. However,
45 days following the initial injury and 14 days after
wound closure, an elevation in the CRP to 2.6, as well as
an increase of purulent drainage from the knee prompted
another surgical exploration of the distal femur and the
addition of intravenous Ambisome, 90 mg (4.8 mg/kg)
daily. At surgery, progressive bone loss was noted as well
as necrosis of knee cartilage. Fungal organisms with irreg-
ular branching hyphae were noted throughout the excised
cartilage, and fungus was recovered in culture two weeks
later.
Meanwhile, the fungal agent that had been isolated previ-
ously was forwarded to the Fungus Testing Laboratory at
the University of Texas Health Science Center in San Anto-
nio for identification and susceptibility testing and acces-
sioned into their stock collection as UTHSC 05-3365.
There, the organism was identified as Myceliophthora
thermophila, based upon observation of: 1) tan to brown
powdery colonies with ill-defined margins when grown
on potato flakes agar at 42°C; 2) more luxuriant growth
at elevated temperatures of 35°C and 42°C than at 26°C;
3) septate vegetative hyphae with conidial production
from ampulliform swellings; and 4) obovoid (inverted
egg shaped) or pyriform (pear-shaped) conidia measuring
4.5–11.0 × 3.0–4.5 µm that were hyaline and smooth
when immature, becoming darker and roughened at
maturity (Figure 1). Antifungal susceptibility testing was
performed according to the Clinical Laboratory Standards
Institute (CLSI) M38-A document for filamentous fungi
[2]. Although standardized susceptibility breakpoints
have not been established for this organism, the isolate
appeared resistant to a variety of standard antifungal
agents (Table 1). Based upon these susceptibilities, vorico-
nazole (4 mg/kg/12 hrs after a loading dose of 6 mg/kg/
12 hrs for 24 hours) was added to the patient's antifungal
regimen, and Ambisome was discontinued. Subsequently,
the patient underwent numerous debridement proce-
dures with gradual improvement in clinical picture and
CRP. A series of progressive increases in voriconazole dos-
age was required based upon periodic pharmacokinetic
studies to achieve appropriate blood levels (Table 2).
Conidia of Myceliophthora thermophila being produced from  ampulliform swellings Figure 1
Conidia of Myceliophthora thermophila being produced from 
ampulliform swellings. Note both smooth, hyaline, immature 
conidia, and darker, more mature roughened conidia. Lacto-
fuschin stain, approximately 1000×.Annals of Clinical Microbiology and Antimicrobials 2006, 5:21 http://www.ann-clinmicrob.com/content/5/1/21
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After his CRP had normalized, the patient was discharged
home receiving voriconazole, 250 mg (13.4 mg/kg)
orally, every 12 hours, and terbinafine 125 mg (6.7 mg/
kg) orally once daily. Anti-fungal therapy is to be contin-
ued for a total of one year. The leg wound has healed, but
the patient has had significant bone loss in his distal
femur with involvement of the growth plate, as well as
damage to the articular cartilage of the knee.
Discussion
Myceliophthora thermophila is a melanized filamentous
hyphomycete that initially grows as a white cottony col-
ony and subsequently turns pale brown and becomes
granular on a variety of media recommended for mould
identification, such as potato dextrose or 2% malt agar. Its
optimal growth is at 30–36°C. However, it also grows
well at 42°C, with maximal growth near 50°C. Thus it is
considered a thermophilic organism. Myceliophthora
thermophila is found in dry pasture soil, birch chips,
wood pulp, and straw compost [1]. Its cell wall contains
melanin resulting in dark pigmentation, and it is consid-
ered one of the etiologic agents of phaeohyphomycosis.
Phaeohyphomycosis includes those conditions in which
the pathogenic mould forms fungal elements which con-
tain melanin within their cell walls [3]. Despite the pres-
ence of melanin, cell walls of phaeoid moulds may appear
hyaline or clear upon routine microscopy. Hyphal ele-
ments usually demonstrate pigment when stained with
Masson-Fontana melanin stain, allowing identification of
a dark fungus [4].
A recent review reports that the number of publications
related to phaeohyphomycotic infections in the 1990's
numbered only 150 [5]. Phaeohyphomycosis most com-
monly manifests as a cutaneous infection, but deep infec-
tions with invasion of the sinuses, lungs, brain, blood,
and bone have also been reported [5]. Disseminated dis-
ease was reviewed by Revankar et al. who found 72 cases
reported between 1966 and 2001 [6]. Notably, the major-
ity of cases involving disseminated phaeohyphomycosis
were in immune-compromised patients. The mortality
rate in these individuals was high and many isolates were
resistant to amphotericin B. In immunocompetent
patients, most infections were associated with direct inoc-
ulation of the organism from an environmentally con-
taminated source.
There are just three previously reported cases of phaeohy-
phomycosis caused by Myceliophthora thermophila
(Table 3). In the first two patients, the source of the Myc-
eliophthora thermophila was uncertain, and both
patients died despite standard anti-fungal therapy with
amphotericin B. The most recently reported case of infec-
tion with this organism involved a 21-month-old boy
who sustained a penetrating head injury. A brain abscess
developed from which both Clostridium perfringens and
Myceliophthora thermophila were isolated. The patient
was treated successfully with enbloc resection of the
lesion, six weeks of amphotericin B, and four months of
itraconazole [9].
Despite convincing evidence of progressive infection in
each of the three previously reported cases, it was not until
well into the clinical course or even after death that iden-
tification of the etiologic agent was confirmed. It is
unknown why recovery of Myceliophthora thermophila
from clinical specimens is so difficult. However, the situa-
tion may be analogous to mycotic infections with more
Table 1: Susceptibilities of Myceliophthora thermophila isolate
Drug MIC







*There are no published breakpoints for this organism against any of 
the antifungal agents tested. Interpretations are based upon normally 
achievable concentrations of the drug using standard dosing regimens.
Table 2: Voriconazole plasma concentrations (body weight 18.6 kg)*
Voriconazole Therapy Day Dose (mg) given every 12 hr Dose (mg/kg) Doses prior to kinetics Peak (mcg/ml) Trough (mcg/ml)
6 75 IV 4 10 0.94a < 0.2
14 108 IV 5.8 8 0.6 < 0.2
24 175 IV 9.4 6 3.04 < 0.2
34 250 PO 13.4 8 2.8b 0.3
43 250 PO 13.4 26 5.35c 0.3
57 250 PO 13.4 54 2.12b 0.2
*Patient also receiving terbinafine 6.7 mg/kg/day
aIV peak @ 50 minutes post infusion
b PO peak @ 2–3 hours post ingestion
c PO peak @ <2 hours post ingestionAnnals of Clinical Microbiology and Antimicrobials 2006, 5:21 http://www.ann-clinmicrob.com/content/5/1/21
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common agents such as Aspergillus, in which microbio-
logic isolation of the etiologic agent from grossly infected
tissue can be difficult. The identification of Mycelioph-
thorathermophila, once recovered, is also problematic, as
most microbiology laboratories lack experience with this
organism.
In our patient, despite evidence of ongoing infection,
both operatively and preoperatively, only two samples of
debrided bone or cartilage yielded Myceliophthora ther-
mophila, despite numerous cultures of infected surgical
specimens in which fungal elements could be seen histo-
logically. Given the thermophilic nature of this organism,
incubation of inoculated media at elevated temperatures
may enhance recovery. Cultures of most clinical speci-
mens are incubated at 30°C, but such a temperature
would be less than optimal for growth of Myceliophthora
thermophila.
Because our patient's positive cultures was obtained after
approximately 2 weeks of terbinafine therapy and the
organism was found to be resistant to amphotericin B,
voriconazole was added to terbinafine therapy. Terbin-
afine is a broad-spectrum allylamine with fungicidal activ-
ity against dermatophyte species, Aspergillus species,
Sporothrix schenckii, Blastomyces dermatitidis, Histo-
plasma capsulatum, Cryptococcus neoformans, Malas-
sezia furfur and other important fungi. It shows in vitro
synergism with amphotericin or triazoles and has been
effective in combination therapy in individual patients
[10-14]. It has been administered safely in a large number
of children, and at high doses or for up to 12 months for
invasive mycoses [15].
Voriconazole is a potent antifungal agent effective against
a number of pathogens, including Aspergillus, Cryptococ-
cus, and Candida species. It also has excellent oral bioa-
vailability and a low rate of adverse effects [16, 17].
However, it is not approved by the Food and Drug Admin-
istration for use in children, and the appropriate dose for
pediatric patients is not known. Recommendations in
authoritative sources suggest the same intravenous
weight-based dosages in children and adults: a loading
dose of 6 mg/kg/dose every 12 hours × 1 day and a main-
tenance dose of 4 mg/kg/dose every 12 hours. Oral dosage
is suggested at 100 mg every 12 hours for patients less
than 40 kg, and 200 mg every 12 hours for patients more
than 40 kg [18].
Recent investigations by Walsh et al. demonstrated that
pediatric patients have a much higher rate of elimination
of voriconazole per unit of body weight than do adults.
Thus, children may require higher dosages to achieve
blood levels consistent with adults treated at a dosage of
3–4 mg/kg [16, 17]. Additionally, the elimination of vor-
iconazole from the blood in children appears linear when
doses of 3 mg/kg to 5 mg/kg are administered every 12
hours. This is in distinction to elimination of similar
doses in adults, which is non-linear or saturable.
Although the exact relationship between the plasma con-
centration of voriconazole and the drug's clinical effec-
tiveness is uncertain, infected adults improve at doses
achieving recommended plasma concentrations. There-
fore, the goal in our patient was to achieve voriconazole
blood levels similar to those achieved in adults. Assuming
linear pharmacokinetics, it was suggested by Walsh that a
pediatric dosage of up to 11 mg/kg twice a day might be
necessary to achieve drug levels equivalent to those seen
in adult patients receiving 4 mg/kg of the agent every 12
hours [17]. We increased the dose of voriconazole in our
patient, in stepwise fashion based upon measurements of
Cmax, from 4 mg/kg to 13.4 mg/kg every 12 hours, reach-
ing a voriconazole serum peak levels in the range of 2–5
mcg/ml, equivalent to the typical adult given only 3–4
mg/kg every 12 hours. Kinetics of voriconazole in our
patient were potentially affected by concurrent adminis-
tration of terbinafine.
The current case demonstrates the vigilance required in
patients with traumatically induced osteomyelitis, partic-
ularly when related to direct implantation from a grossly
contaminated source. Relapse of apparently appropriately
treated infection while on therapy demands reassessment
to be certain that an unusual or emergent microorganism
is not present within the depths of the wound. In the case
of a contaminated farm implement, the possibility of
recovery of an unusual agent like Myceliophthora ther-
mophila is high, potentially requiring the usage of antimi-
crobial agents for which there is scant pharmacologic data
in children. Clinicians should be careful to obtain appro-
priate pharmacologic studies in order to be assured that
the appropriate doses of such drugs are employed.
Table 3: Prior Case Reports of Myceliophthora thermophila infection
Age, Sex History Sites of Infection Therapy Outcome
7 years, M7 AML with neutropenia Blood, lungs, heart Amphotericin B Death
22 years, F8 Status post Cardiovascular Surgery Blood, aorta, heart Amphotericin B 5-fluorocytosine Death
21 months, M9 Penetrating head injury from a rusty nail in a barnyard. Brain 
abscess with M.thermophilia and Clostridium perfringens
Brain abscess Amphotericin B Itraconazole SurvivedPublish with BioMed Central    and   every 
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